Determination 2
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Arms / Cohorts
Experimental:Arm D: Cohort 1 Maintenance Therapy Part 2, Iberdomide + Isatuximab
Not yet accepting
Other:Arm A: Induction and Screening
Not yet accepting
Active Comparator:Arm E: Cohort 2 Randomized Consolidation and Maintenance (HDM-ASCT Strategy)
Not yet accepting
Experimental:Arm B: Cohort 1 Maintenance Therapy Part 1
Not yet accepting
Experimental:Arm F: Cohort 2 Randomized Consolidation and Maintenance (Linvoseltamab Strategy)
Not yet accepting
Experimental:Arm C: Cohort 1 Maintenance Therapy Part 2, Single-Agent Iberdomide
Not yet accepting
Other:Arm G: Cohort 2 Non-randomized 3-Drug Maintenance
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.